secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fortress Biotech, Inc. (FBIO)
CIK:        0001429260
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001558370-25-011561
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fortress Biotech posts Q2 net income $13.4M; Checkpoint acquisition yields $28M upfront
--------------------------------------------------------------------------------

- Checkpoint acquired by Sun Pharma in May; Fortress received ~$28M at close, up to $4.8M CVR, plus 2.5% royalty on UNLOXCYT sales.
- FDA accepted CUTX-101 NDA for priority review; PDUFA goal date September 30, 2025.
- Q2 consolidated net revenue $16.4M ($15.0M from dermatology); net income $13.4M vs net loss $13.3M a year ago.
- Consolidated cash $74.4M as of June 30, up from $57.3M at Dec 31, 2024, boosted by Checkpoint proceeds.
- Emrosi commercial launch underway; payer coverage expanded to 100M U.S. commercial lives as of July 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1429260/000155837025011561/0001558370-25-011561-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1429260/000155837025011561/fbio-20250814x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-011561

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer